You just read:

PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

News provided by

PTC Therapeutics, Inc.

Jun 07, 2019, 13:31 ET